Hematologic Malignancies Talk: Exciting Updates from ASH 2020 Virtual Meeting - Episode 3

ASH 2020 Updates in Relapsed/Refractory B-Cell Lymphomas

January 22, 2021
Jennifer Woyach, MD, Ohio State University

,
Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute

,
Nathan H. Fowler, MD, MD Anderson Cancer Center

,
Sarah Rutherford, MD, Weill Cornell Medical College

A discussion on updates presented at the ASH (American Society of Hematology) 2020 Annual Meeting on developments in the management of relapsed/refractory B-cell lymphomas.

Data from the following clinical trials are discussed:

  • Abstract 339: Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial

  • Abstract 403: Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma

  • Abstract 2104: A Phase I Investigator Sponsored Trial of Selinexor (KPT-330) and Rituximab, Ifosfamide, Carboplatin and Etoposide in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas

  • Abstract 599: Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study

  • Abstract 598: Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis

x